NCT01414803

Tolerability and Efficacy of Rosuvastatin - Fenofibrate Combine Therapy in Korean Patients With Combined Hyperlipidemia

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 180 (actual)
• Sponsor: Yonsei University · Academic / Other
• Sex: All
• Age: 20 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Although the combination of statin and fenofibrate is one of the options for patients with combined hyperlipidemia, non-lipid effects of it has not been completely understood yet. In this study we compared the effects of rosuvastatin 10 mg/fenofibrate 160 mg combination and rosuvastatin 10 mg monotherapy on muscle and liver enzyme, homocysteine levels, kidney, blood glucose control, and blood cell counts.

Conditions

• Hyperlipidemia

Interventions

Type	Name	Description
DRUG	Lipid modification	rosuvastatin 10 mg/fenofibrate 160 mg per day
DRUG	Lipid modification	rosuvastatin 10 mg per day

Timeline

• Start date: 2009-03-01
• Primary completion: 2011-04-01
• Completion: 2011-04-01
• First posted: 2011-08-11
• Last updated: 2011-08-11

Locations

1 site across 1 country: South Korea